Page 248 - ebook HCC

EASL HCC SUMMITHCC SUMMIT
GENEVA, SWITZERLANDA, SWITZERLAND
PROGRAMME AND ABSTRACTSAND ABSTRACTS
246 PROGRAMME GENEV EASL 247
246
247
FEBRUAR
FEBRUARY 13 - 16, 2014Y 13 - 16, 2014
Poster Board Number C32
COMPARISON OF SURVIVAL OF Etiology of liver disease was alcoholic cirrhosis/ chronic hepatitis C/ chronic hepatitis
HEPATOCELLULAR CARCINOMA PATIENTS IN B/ NASH/ other liver diseases in 163 (35.6%)/ 87 (19%)/ 48 (10.5%)/ 21 (4.6%)/ 110
(24%). Comparing the periods the number of pts with chronic hepatitis C decreased
STAGE BCLC C BEFORE AND AFTER APPROVAL significantly (P1: n= 54 (25.5%), P2: n= 33 (13.4%), p< 0.05). Child-Pugh score A/B/C
OF SORAFENIB was 47.6%/27.4%/2.4% in P1 vs. 29.7%/39.8%/1.2% in P2 (p=0.153). There was no
significant difference in the presence of portal vein thrombosis (P1: 41% vs. P2: 37.8%) or
in the presence of ascites between the periods (P1: 19.8% vs. P2: 17.5%, p= 0.637). The
median tumor size was significantly higher in P1 7 cm vs. 6.3 cm (p<0.05).
Arndt Weinmann , Sandra Koch , Martin Sprinzl , Henning Schulze-Bergkamen , Transarterial Chemoembolisation (TACE) was used in 91 (42.9%)/75 (30.5%) of patients
1 2
1 2
1 2
3
Christoph Düber , Hauke Lang , Gerd Otto , Peter R. Galle , Marcus Wörns 1 2 in P1/2 (p=0.07). The resection rate was 17.9% in P1 vs. 24% in P2 (p=0.218).
1
5
4
6
1 Ist Medical Department, Clinical Registry Unit, University Medical Center of the Sorafenib was used in 10 pts in P1 (4.7%) and 61 pts (24.8%) in P2 and in 0 (0%) in P1
2
3
Johannes Gutenberg University Mainz, Mainz, Department of Medical Oncology, and 30 pts (12.2%) as the firstline therapy.
National Center for Tumor Diseases (NCT), Heidelberg, Department of Diagnostic and Median OS was significantly longer in P2 (10.2 months) compared to P1 (7.8 months, p<
4
Interventional Radiology, Department of Department of General, Visceral and Transplant 0.05).
5
6
Surgery, Department of Transplantation and Hepatobiliopancreatic Surgery, University
Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany Conclusions: While OS improved significantly between periods P1 and P2, but the
number of patients treated with sorafenib was low. Further analysis is needed to evaluate
Corresponding author’s e-mail: weinmann@mail.uni-mainz.de the contribution of Sorafenib to the OS improvement between periods.

Introduction: Sorafenib demonstrated a significant improvement of overall survival (OS)
for patients with hepatocellar carcinoma (HCC) in in two phase III trials. Since its approval
in 2007 it became the standard of care for patients in stage BCLC C. So far, efficacy of
sorafenib in rouine clinical prectice needs to be defined.
Aims: To compare the OS of a western cohort of HCC patients in stage BCLC C before
and after the approval of Sorafenib.
CLINICAL POSTER ABSTRACTS Center of the Johannes Gutenberg-University Mainz between 2001 and 2012. Data was CLINICAL POSTER ABSTRACTS
Methodology: Retrospective analysis of HCC patients treated at the University Medical
extracted from our clinical registry. The cohort was separated into two groups on the basis
of the year of initial diagnosis: P1: 2001 to 2006 and P2: 2007 to 2012. Patients who
received a liver transplantation were excluded from the analysis. The OS was appraised
by the Kaplan-Meier method.
Results: 458 of 1251 pts were classified as stage BCLC C between 2001 and 2012
(median age 66 years, 85.2% male), 212 in P1 (median age 66 years, 82.5% male) and
246 in P2 ( (median age 67 years, 87.4% male).